Agenus Falls After $141M Zydus Deal Closes

Dow Jones

01/16

By Katherine Hamilton

Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences.

Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months.

Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash.

The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece.

Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders.

Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 15, 2026 13:29 ET (18:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603980629"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603980629\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603980629?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 02:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603980629","market":"nz","top_or_hot":-1,"title":"Agenus Falls After $141M Zydus Deal Closes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences. \n</p>\n<p>\n  Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months. \n</p>\n<p>\n  Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash. \n</p>\n<p>\n  The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece. \n</p>\n<p>\n  Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders. \n</p>\n<p>\n  Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2026 13:29 ET (18:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Falls After $141M Zydus Deal Closes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Falls After $141M Zydus Deal Closes\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-16 02:29</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences. \n</p>\n<p>\n  Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months. \n</p>\n<p>\n  Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash. \n</p>\n<p>\n  The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece. \n</p>\n<p>\n  Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders. \n</p>\n<p>\n  Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2026 13:29 ET (18:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGEN","symbol_name":"艾吉納斯公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603980629","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603980629","pubTimestamp":1768501740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences.Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months.Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash.The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece.Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders.Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGEN":"艾吉纳斯公司","BK4139":"生物科技"},"translate_title":"1.41亿美元Zydus交易完成后Agenus股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences. \n\n\n  Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months. \n\n\n  Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash. \n\n\n  The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece. \n\n\n  Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders. \n\n\n  Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2026 13:29 ET (18:29 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}